Inamoto Y, Chiba T, Sakane K, Kamimura T, Takaya T
New Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Yakugaku Zasshi. 1990 Apr;110(4):246-57. doi: 10.1248/yakushi1947.110.4_246.
Various 7 beta-[2-(2-aminothiazol-4-yl)-2-substituted acetamido]-3-vinyl-3-cephem-4-carboxylic acid derivatives (Ia--e, IIa--g) were synthesized in order to find a new orally active cephalosporin improving the antibacterial activity of cefixime (CFIX) against Staphylococcus aureus. These derivatives include three types of alpha-substituted 2-(2-aminothiazol-4-yl)acetyl side chain; i) mono or non substituted acetyl moiety, ii) carboxyalkoxyimino acetyl moiety, iii) phosphonomethoxyimino and hydroxyimino acetyl moiety. Their structure-activity relationships and urinary recoveries in rats were studied. As a result, the compound with a hydroxyimino acetyl side chain (IIg, FK482) showed good oral absorption and excellent antibacterial activity against both gram-positive and gram-negative bacteria and was selected as a candidate for clinical trial.
为了找到一种新型口服活性头孢菌素,以提高头孢克肟(CFIX)对金黄色葡萄球菌的抗菌活性,合成了多种7β-[2-(2-氨基噻唑-4-基)-2-取代乙酰胺基]-3-乙烯基-3-头孢烯-4-羧酸衍生物(Ia - e,IIa - g)。这些衍生物包括三种类型的α-取代2-(2-氨基噻唑-4-基)乙酰基侧链;i)单取代或未取代的乙酰基部分,ii)羧基烷氧基亚氨基乙酰基部分,iii)膦酰基甲氧基亚氨基和羟基亚氨基乙酰基部分。研究了它们的构效关系和在大鼠体内的尿回收率。结果,具有羟基亚氨基乙酰基侧链的化合物(IIg,FK482)显示出良好的口服吸收以及对革兰氏阳性菌和革兰氏阴性菌均具有优异的抗菌活性,并被选为临床试验候选药物。